Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
9,909 results
  • Is Antiretroviral Two-Drug Regimen the New Standard for HIV Treatment in Naive Patients? [Journal Article]
    AIDS Rev 2019; 21(3):143-156Dupont E, Yombi JC
  • The use of a combination antiretroviral therapy (cART) has changed dramatically the prognosis and the life expectancy of people living with HIV. The current treatment guidelines continue the convention of preferred cART based on combining a dual nucleoside reverse-transcriptase inhibitor (NRTI) backbone with a third "anchor" agent, such as a ritonavir (r)- or cobicistat (c)-boosted protease inhib…
  • A long acting nanoformulated lamivudine ProTide. [Journal Article]
    Biomaterials 2019; 223:119476Smith N, Bade AN, … Edagwa B
  • A long acting (LA) hydrophobic and lipophilic lamivudine (3TC) was created as a phosphoramidate pronucleotide (designated M23TC). M23TC improved intracellular delivery of active triphosphate metabolites and enhanced antiretroviral and pharmacokinetic (PK) profiles over the native drug. A single treatment of human monocyte derived macrophages (MDM) with nanoformulated M23TC (NM23TC) improved drug …
  • Pharmacokinetics of Co-encapsulated Antiretrovirals with Ingestible Sensors. [Journal Article]
    AIDS Res Hum Retroviruses 2019Liu H, Daar ES, … Fletcher C
  • We investigated the use of a system with an ingestible sensor (Proteus Digital Health Feedback system) co-encapsulated with antiretrovirals (ARVs) to measure real-time adherence. To assess the safety and impact, if any, co-encapsulation might have on ARV concentrations, we evaluated the pharmacokinetics of ARVs co-encapsulated with an ingestible sensor for eight commonly used fixed-dose combinati…
New Search Next